Mind the Gap: Pharma Chasing Biotech Assets

Validation with big pharma – is it still necessary? Depends on who you talk to. This was one of several questions posed to panelists at today’s business roundtable session. Arguments can be made on both sides, but one thing is for certain, the life sciences financing community has become much more sophisticated in recent years. And biotech and pharma companies have become more sophisticated in doing deals because they have a lot more experience to draw from. That’s definitely a win-win for everyone involved.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: